Track topics on Twitter Track topics that are important to you
Way back to the history, over the past 50 years nuclear medicine sector has displayed a strong link between investments in chemistry and development of radionuclide's and radiolabeled compounds. This advancement has majorly impacted the health care practice. In the present scenario nuclear medicine is considered to be one of the diagnostics and therapeutic modality technique for probing, tracking and treating diseaserelated tissue function, progression and treatment response. Noninvasive nuclear medicine imaging technique provides functional information at both molecular and cellular level and helps measuring the uptake and turnover of targetspecific radiotracers in tissue.
Radioisotopes are used in a wide variety of applications like oncology, cardiovascular and neurological disorders. But in recent times, advancements in the field of nuclear medicine and radioactive tracers have emerged to provide few practical methods for studying the limited metabolic activities of bones and teeth, hence has found a role in dental science research.
According to IQ4I analysis, the global nuclear medicine/radiopharmaceutical market is expected to reach 9,275.3 million by 2022. Nuclear medicinal market is mainly classified into type diagnosis therapeutics, application and endusers. The global nuclear medicine market by diagnosis is further divided into SPECT and PET while therapeutics market is segmented into alpha radiation therapy, beta radiation therapy and brachytherapy.
The SPECT and PET diagnostics market is further divided into isotopes and application. SPECT market by isotopes includes technetium Tc99m, thallium Tl201, gallium Ga67, iodine I123, samarium Sm153, yttrium Y90, rhenium Re186 and others. SPECT by applications are classified into cardiology, gastro intestinal, oncology, nephrology, neurology, inflammation, thyroid glands, lymphology and others. The PET diagnostic market by isotopes involves fluorodeoxyglucose 18fFDG, gallium Ga68, rubidium Rb82 and others. PET applications are segmented into cardiology, oncology, neurology, inflammation, thyroid and others.
The alpha radiation therapy includes actinium Ac225, astatine211 At211, lead Pb212/bismuth Bi212, radium Ra223, radium224 Ra224, thorium227 Th227 and others. The isotopes considered in beta radiation therapy are erbium Er169, iodine I131 lutetium Lu177, rhenium Re186, samarium Sa153, strontium Sr89, yttrium Y90 and others. The final therapeutic segment brachytherapy involves cesium Cs131, iodine I125, iridium Ir192, palladium Pd103 and others
The nuclear medicine market endusers include medical, academic research laboratories and industries. The endusers by medical further segmented into hospitals and diagnostic centers.
The nuclear medicine/radiopharmaceutical market includes stable isotopes section as well which is classified into isotopes and applications. Isotopes considered are carbon C13, deuterium D2, oxygen O18, nitrogen N15, sulphur S32 and others. The stable isotopes have application in diagnostics and therapy, pharmaceutical companies, research section and industrial sector. The leading players of this market are Cambridge Isotope Laboratories U.S and Isotec Inc. subsidiary of Sigma Aldrich U.S..
The nuclear medicine/radiopharmaceuticals market is expected to grow at single digit CAGR during 2015 to 2022. The factors driving the growth of this market are increased application of radiopharmaceuticals, rise in public awareness, usage of hybrid imaging, abundance of radio pharmaceuticals, technological advancements; alpha radio immunotherapy based targeted cancer treatment and wide range of available products likely to propel the nuclear medicine market. In addition to this, increasing need in emerging markets, production of radio pharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes, increasing therapeutic application areas and replacement of old/traditional equipment are some of the opportunities that are propelling the growth of the market. However, regulatory issues, high cost and supply shortage of isotopes, shorter half life of radiopharmaceuticals, and threat from traditional/alternative diagnostic procedures are hampering the growth of the market. The threats for the nuclear medicine/radiopharmaceuticals market include huge capital investment and shortage of qualified technicians. The major problem area of nuclear medicine market is closure of reactors.
The nuclear medicine/radiopharmaceuticals global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the nuclear medicine market are Bayer Healthcare Germany Cardinal Health Inc. U.S., Cambridge Isotope Laboratories U.S, GE Healthcare U.K., IBA Group Belgium, Isotec Inc. U.S. Lantheus Medical Imaging U.S., Mallinckrodt Plc Ireland, NTP Radioisotopes South Africa, Nordion Inc Canada Siemens Healthcare Germany and Taiyo Nippon Sanso Corporation Japan.
The report provides an in depth market analysis of the above mentioned segments across the following regions:
Rest of the World RoW
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...